Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What about lichtenstein and Moldova coming on board ?
Yea I have to agree, taking profits, punk will get back on bigger teeter totter
Punk getting knocked off teeter totter - suspect he gets back on later in the week
WIll PUnk get knocked off teeter totter ??
Isnt it fun doing AMRN's work for them Execs getting millions of dollars in stock bonuses and here you are doing all the work
Jarvator, Vastorance ?
Lrich there's an old sayin
If you wrestle with a pig - you are bound to get dirty
Exactly triple combo pill !!
Question PDUDE / LAwyers - which probably can't be answered
FDA required AMRN to perform REDUCE IT to produce intellectual property that EPA reduces CAD risk. SInce AMRN paid to produce that intellectual property why is it not protected? Lets say I produce an antigravity machine and patient it . WHat right does someone else have to steal my intellectual property that I spent millions in developing to prove that concept ?
Exactly so make some dough riding the teeter totter . Mama bakes shortnin bread punk rides teeter totter and we all make money !
Punk rides teeter totter Buy at $1:10 short at $1:30
Yes this playground gets played ...lol
Correct but I am certain those studies are coming next and the problem is BP will position this in the minds of HCP's as THE drug they need to choose along with statins for CAD. ( I can tell by the questioning I am receiving ) . They are connecting the dots between CAD CRF and DM2 bringing them under one common physiology to thereby capture the entire CAD market under the presumption that CAD occurs along this common pathway .
https://www.frontiersin.org/articles/10.3389/fcvm.2022.882181/full
The results showed that the risk reduction of myocardial infarction in the secondary prevention cohort was more significant than that in the primary prevention cohort
AS we all have learned its not about the science ( as long as its not a false narrative) its about the marketing
Correct
Talshu - How is Hungary ?
NO longer AMRN no longer Eunucha now Grifters INC
Performing numerous consultations for firms on SGLT's and their role in CAD risk reduction - BP prepping to make SGLT's the go to preventative medication for CAD. But of course Grifters Inc is on top of this
Interesting that Optical coherence tomography and CCTA (Computer tomography) reveals reduction but ultrasound not
Iwanderer Fascinating punk not going beyond $1:30 so far staying on the teeter totter
Iwanderer AMRN punk riding teeter totter is at $1:30. As per my modus operandi I have been buying near $1:10 and selling at near $1:30 shortnin back to $1:10
Do you think punk getting kicked off and may ride higher ? I might hold and not short this time around.
Talshu your studious and logical approach is reminiscent of other savants that rotated through this site - fascinating indeed
Whats the impetus ?
PUnks on the teeter totter until Denner or Health Net case knocks him off
Fascinating indeed, maybe we should change the companies name once again to GRIFTERS INC ....lol
Well then AMRN can market a drug that cant be sold as its not been approved, that's reassuring. LOL
JOINT STUDY WITH BP
If Eunucha ( formerly AMRN) was a competent company they would approach BP and ask for a joint study with Vascepa and an SGLT - but of course that would require competent management forward thinking and concern about SP instead of where should I get my condo in Switzerland
Remember you can always try to make some money shorting. For me the only potential quantum leap forward for this company is HEalthnet . In the past I felt health net case had a great chance of winning. From what I am now seeing with this company I have reduced that percentage significantly.
Without the HEalthnet case they are relegated to some backwater wannabe company and will be pushed aside by BP and SGLT's
YOu are dreaming . The only way it gets sold for $20 is if share price begins to push beyond $10. The only action thing that will do that is winning the healthnet case .
Odd, KM did not mention Moldova or Lichtenstein
EUNUCHA will not respond
Clowns don't usually hire another competent professional they usually hire another clown
Never did a study with Vascepa alone in statin intolerant patients
Never did a combo study with SGLT's
Never stood up to Nissen
Never explained to INsurance companies the difference between Lovaza and pure EPA
the list goes on and on ....
Denner needs to clean house and the sooner the better
I dont deny the value of Vascepa as a medication. I deny the ability of AMRN to move it forward. That has been the message I have been trying to get across to this board for about 6 months now. It seems that many have now reached that conclusion including Mr. Denner. One must first confront the reason for their failures before it is possible to advance, we are now at that stage.
Interesting perspective Jroon
I dont recall Denners avg buy in price but I think it was somewhere around $4 . If he can double his money in two years hes doing great - I dont think he would sell for under $8 but I could be wrong. That means he has to get the stock to at least $4 as buyout at more than 100% are rare
Great opening paragraph which every investor here should understand
Irishman this is an investment site . I believe investors are people who wish to make money from investing . You are correct, I sit on both sides of the fence Hence if you have read my post I use the analogy of a teeter totter . It goes up and down and I am trying to make money on each swing. This is my first time as a short term investor and thus far it has worked out well.
I am not here to blindly cheer for a company or medication, that is NOT what investments are about . People on this site cannot accept negative news about the stock, they tend to take it personally. Negative news about the stock or product is NOT negative news about them. Remaining objective to make money is the purpose. The analogy is why physicians should not treat family. You are too emotionally invested to make rational decisions. People who interpret negative news about the stock as negative news about them are too emotionally invested to be objective and that does not make a good investor.
I am trying to help people be objective to understand that even bad news can be used to make money because once again this is an investment site.
I see BP positioning themselves to take SGLT's as the premier preventative medication for CAD. KIWI made the point about revascularization which is a great scientific point. However , as I have learned and having been trying to get poepl to understand this matters not. BP will push their product and eclipse Vascepa . That's just reality. Are they ways to counter this ? Certainly. DO I think AMRN's current management has that capability - a resounding NO.
DO I hold any hope out for Vascepa ? Yes. I think the Healthnet case is the lynch pin. Currently there is no reason to educate docs to sell generics. If they get infringement protection then they can market to providers and establish a market presence increase sales and sell out to BP.
In the meantime why not make some money riding that teeter totter ?
Kiwi you have to change your mindset and understanding . Vascepa may be better at reducing CAD risk but as I have said science alone is not enough to launch a successful pharmaceutical .
Vascepa doesn't reduce CRF and doesn't work directly on DIabetes > Here's the take-home - BP will paint the narrative that DM2, CRF and CAD are all interrelated and the only meds that attacks all 3 are SGLT's. Therefore if you want to attack this common pathway for induction of CAD the oNLY meds that do that are SGLT's
WIth that marketing capability they destroy any market Vascepa has
Having a 4 years supply and 75% markup matters not if the product cannot be sold. WHat would be interesting is a study on a combo med ,statin Vascepa and SGLT and overall effect on cardiovascular mortality